BioCentury on BioBusiness,
Good news travels fast
Monday, July 21, 1997
Ebb & Flow
After the spate of bad news in the sector over the past month, it's encouraging to find that investors still are willing to reward companies for good news. Aviron (AVIR) jumped $3.75 to $17.125 on Monday after releasing positive Phase III results of its intranasal flu vaccine (see BioCentury Extra, July 15). Tuesday, the stock soared $6.875 to $24 on 3.7 million shares after the data were widely publicized in both print and television media. The stock was up 74 percent on the week, closing at $23.25. . . . MedImmune (MEDI) gained $5.312 to $24.937 on Wednesday after announcing positive Phase III data for its MEDI-493 antibody for respiratory syncytial virus (see BioCentury Extra July 17). MEDI's market cap increased by $128.7 million on the week, as the stock closed up 33 percent at $23.875. . . . Interneuron (IPIC) added $1.25 to $19.125 on Wednesday after the company announced Phase III data for its
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]